GDC-0084 With Radiation Therapy for People With PIK3CA-Mutated Solid Tumor Brain Metastases or Leptomeningeal Metastases

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE1

Total Enrollment

21 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-12-06

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will test the safety of the study drug, GDC-0084, in combination with radiation therapy in people who have solid tumor brain metastases or leptomeningeal metastases. All participants will have cancer with a PIK3CA mutation. The researchers will test increasing doses of GDC-0084 to find the highest dose that causes few or mild side effects in participants. The study will also try to find out if the combination of the study drug with radiation is effective against participants' cancer.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of the Combination of Vorinostat and Radiation Therapy for the Treatment of Patients With Brain Metastases

NCT00838929

Brain Metastases

COMPLETED PHASE1

Ph I Study of Lithium During Whole Brain Radiotherapy For Patients With Brain Metastases

NCT00469937

Brain and Central Nervous System Tumors Cognitive/Functional Effects Neurotoxicity +1 more

TERMINATED PHASE1

Chemotherapy Followed by Radiation Therapy in Treating Adults With Supratentorial Glioma

NCT00002806

Brain and Central Nervous System Tumors

COMPLETED PHASE2

Motexafin Gadolinium, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma

NCT00305864

Adult Giant Cell Glioblastoma Adult Glioblastoma Adult Gliosarcoma

COMPLETED PHASE1/PHASE2

Vorinostat and Concurrent Whole Brain Radiotherapy for Brain Metastasis

NCT01600742

Brain Metastasis

TERMINATED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Brain Metastases Leptomeningeal Metastasis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Single-arm, prospective trial

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Concurrent GDC-0084 with Radiation

GDC-0084 in 3 + 3 dose-escalation in 3 cohorts: 45, 60, 75 mg daily, with a potential de-escalation cohort to 30mg, to determine MTD in combination with whole brain radiation therapy radiation therapy to 30Gy in 10 fractions. Once MTD is determined, 12 additional patients will be treated with GDC-0084 at MTD in combination with whole brain radiation therapy.

Group Type EXPERIMENTAL

GDC-0084

Intervention Type DRUG

GDC-0084 in 3 + 3 dose-escalation in 3 cohorts: 45, 60, 75 mg daily

whole brain radiation therapy radiation

Intervention Type RADIATION

30Gy in 10 fractions

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

GDC-0084

GDC-0084 in 3 + 3 dose-escalation in 3 cohorts: 45, 60, 75 mg daily

Intervention Type DRUG

whole brain radiation therapy radiation

30Gy in 10 fractions

Intervention Type RADIATION

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologically confirmed solid tumor malignancies harboring PIK3CA mutations which include mutations in any of the following genes: PIK3CA, PIK3CB, PIK3CD, PIK3CG, PIK3R1, PIK3R2, PIK3R3, PIK3C2G, PIK3C3, INPP4A, INPP4B, INPPL1, INPP5D, PTEN, AKT1, AKT2, AKT3, and MTOR.
* Brain metastases and/or leptomeningeal metastases involving the brain demonstrated by MR imaging of the brain. For patients with brain metastases, measurable lesion by RANO-BM is required28. Patients with spine leptomeningeal metastases are eligible for the study if they have leptomeningeal metastases of the brain demonstrated by MRI imaging of the brain.
* KPS ≥ 70
* Age ≥ 18 years
* Able to provide informed consent.
* If a patient is on corticosteroid, he/she must be on a stable daily dose of \< 4mg dexamethasone or equivalent. Patient does not need to be given corticosteroid as prophylaxis if not clinically indicated.
* No limit to prior therapies with the last systemic therapy ≥ 1 week from initiation of protocol therapy. Systemic therapy can resume after completion of protocol DLT assessment period.
* Patients with prior SRS are eligible, provided that there are new, non-irradiated brain lesions or leptomeningeal metastases. Patients must be ≥ 3 months post prior cranial radiation therapy.
* Patients with seizure history related to brain metastases or leptomeningeal metastases controlled on antiepileptic medications are eligible.
* Patient at reproductive potential must agree to practice an effective contraceptive method
* Patient must be able to swallow and retain oral medication
* Adequate organ function as assessed by laboratory tests.
* Adequate bone marrow function

* Hemoglobin ≥ 8g/dL
* Absolute neutrophil count ≥1,000/mm\^3
* Platelet count ≥ 100,000/mm\^3
* Adequate liver function

* Bilirubin ≤1.5 times upper limit normal (ULN)
* AST and ALT ≤ 2.5 times ULN
* Alkaline phosphatase ≤ 2 times ULN
* Adequate renal function ° BUN and Creatinine ≤ 1.5 times ULN

Exclusion Criteria

* Previous radiotherapy to the intended treatment site that precludes developing a treatment plan that respects tissue tolerances
* Patients with brain metastases eligible for single fraction stereotactic radiation therapy
* Serious medical co-morbidities precluding radiotherapy
* Insulin-treated diabetes; subjects with diabetes or impaired glucose tolerance that is not treated with insulin may be enrolled
* QT interval ≥ 450 msec on EKG
* Cardiac dysfunction defined as: myocardial infarction within 6 months of study entry, NYHA Class II/III/IV heart failure, unstable angina or unstable cardiac arrhythmias
* Known hypersensitivity or intolerance to GDC-0084 or to any other inhibitor of the PI3K/ Akt/ mTOR pathway
* Past medical history of interstitial lung disease, drug-induced ILD, radiation pneumonitis that required steroid treatment, or any evidence of clinically active interstitial lung disease
* Subject receiving any medications or substances that are moderate and/or potent enzyme inducers or inhibitors which may have an effect on the metabolism of GDC-0084.
* Pregnant or lactating women.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No